The ability of viruses to selectively target, replicate within, and destroy tumour cells without deleterious effects in normal cells (oncolysis), makes the use of viruses as an attractive tool for cancer treatment. Pancreatic adenocarcinoma, being insensitive to traditional therapy and having a rather poor prognosis, represents a suitable target to evaluate viral oncolysis as a novel therapeutic approach. Herpes simplex virus (HSV) has been reported to produce an oncolytic effect in cells overexpressing Ras. As Ras signalling is frequently aberrant in pancreatic cancer, we compared four pancreatic cell lines (which differ in the presence of mutated or wild-type ras) for their ability to support growth of g34.5-replication attenuated HSV-1 (R3616). Our data show that permissiveness to viral replication is neither associated with enhanced Ras signalling nor with defective PKR activity. By contrast, we provide evidence that disregulation of the PI 3-kinase signalling pathway allows conditionally replication-defective R3616 virus to overcome the cellular antiviral activity.
Introduction
Pancreatic cancer is one of the most aggressive tumours, characterized by a high propensity to infiltrate and metastasize early from a small primary focus. Being refractory to conventional therapies, it represents an excellent target for innovative therapeutic approaches. 1 Gene therapy is currently in the spotlight as a promising new method for the treatment of pancreatic cancer. 1 Many studies have revealed the potential of this therapy, and early clinical trials are taking place to evaluate the success of gene therapy regimes in humans. 2 In particular, oncolytic virus therapy appears to be a feasible treatment for pancreatic cancer. 1 Engineered or naturally occurring oncolytic viruses take advantage of certain unique features of cancer cells to selectively replicate in and kill neoplastic cells. 3 Cellular defence mechanisms against viral infection represent one of the most important and complex aspects of virus-host interactions. In this context, during replication doublestranded or highly structured viral RNA molecules are produced. By binding to these RNAs, the host cell serinethreonine-kinase PKR is activated and, in turn, it can phosphorylate the translation initiation factor eIF2a, thus inhibiting protein synthesis. 4 Herpes simplex virus-1 is a neurotropic DNA virus that infects a large proportion of the human population. 5 Herpes simplex virus-1 genome contains the gene g 1 34.5 whose product, ICP34.5, associates with the host cell phosphatase PP1a redirecting it to dephosphorylate eIF2a, thus overcoming cellular defense. 6 Herpes simplex viruses have a natural ability to infect, replicate in, and lyse a variety of malignant tumour cells. 7 A virus attenuated by deletion of the g 1 34.5 gene would exhibit wild-type replication only in cells with an endogenous anti-PKR mechanism. 6 Interestingly, in Ras-transformed cells, PKR activity appears to be inhibited: indeed, it has been reported that downstream effectors of Ras can prevent PKR activation. 8 The Ras proteins are members of a large superfamily of lowmolecular-weight GTP-binding proteins. GTP-bound Ras is able to bind and activate effector enzymes, therefore controlling cellular proliferation, survival and other aspects of cell behaviour that can contribute to the transformed phenotype. 9 It has been shown that reoviruses can take advantage of alterations in the Ras/PKR pathway, leading to lytic infection only in malignant cells but not in normal cells which they infect abortively. 10 Viruses that cannot reverse PKR activation by themselves would theoretically become, in this way, dependent on an active cellular Ras pathway for replication. On the other hand, viruses possessing PKR-inactivating functions could be rendered Ras-dependent if these functions are deleted. This has been recently demonstrated in cells intrinsically nonpermissive to HSV-1 replication, artificially transformed with Ras-expressing constructs and infected with a g 1 34.5-deleted HSV-1 virus. 11 Reported data seem to indicate the possibility of employing conditionally replication-defective HSV-1 mutant for oncolysis of tumour cells overexpressing Ras. Indeed, a g 1 34.5-deleted virus would replicate and kill only Ras overexpressing cells.
Ras is mutated at codon 12 in more than 90% of pancreatic cancer specimens. 12 This mutation results in constitutive activation of intracellular signalling pathways, 12, 13 leading to cellular proliferation and thus conferring transformed features.
Based on these observations, with the final goal of developing a selective and safe therapeutic approach, we investigated the ability of a g 1 34.5-deleted HSV-1 to lyse pancreatic tumour cell lines. In particular, by comparing different pancreatic tumour cell lines, characterized by either a wild-type or a mutated ras gene, we analysed the correlation between Ras and viral replication.
Here we demonstrate that Ras activation state is not the major player in permissiveness of pancreatic tumour cells to HSV-1 replication. By contrast, we show evidence that a misregulated PI 3-kinase pathway, by affecting translation initiation control, allows g 1 34.5-deleted HSV-1 to overcome the PKR-mediated cellular antiviral response.
Results

HSV-1 replication in human pancreatic cancer cells in vitro
To assess whether the replication of a g 1 34.5 HSV-1 mutant is Ras-dependent in pancreatic tumoural cells, we used HSV-1 R3616, which contains a 1 kb deletion in both g 1 34.5-encoding regions, and four pancreatic adenocarcinoma cell lines as target. The relevant genotype features, with regard to the ras gene, of these cell lines were confirmed by sequencing (data not shown and data reported by Moore et al.) . 9 The PaCa-3 cell line is characterized by the wild-type K-ras gene, the PSK-1 and MiaPaCa-2 cells present the oncogenic K-ras mutation at the 12 codon (Gly to Arg), whereas the PT45 cell line displays the K-ras mutation at the 13 codon (Lys to Asp). 9 In order to investigate the effect of Ras genotype on the protein activity, we used a commercially available Ras activity assay kit, which is based on the fact that only activated Ras (Ras-GTP) can bind to the RBD of Raf-1.
14 Active GTP-bound Ras was pulled down from cell lysates with the GST-Raf1-RBD coupled to glutathione agarose, and the fraction of activated Ras was determined by immunoblotting with a Ras antibody. The results are reported in Figure 1 and show a very nice correlation between the sequencing data and the actual activation state of the Ras protein. In addition, tested by proliferation assay, the four cell lines did not show any significant difference in kinetics of replication (data not shown).
The cells were infected with HSV-1 at the multiplicity of infection (MOI) of 10 PFU/cell and viral production at various time points post infection (p.i.) was analysed by a standard plaque assay. As shown in Figure 2 , there is no correlation between R3616 viral yields and the ras genotype of the pancreatic cell lines. Thus, our data indicate that Ras is not the major player in permissiveness of tumour pancreatic cells to g 1 34.5-mutant HSV-1 replication.
To examine whether, despite Ras mutations, cells were equally permissive to HSV-1 R3616 replication because of a defective PKR function, we analysed PKR activity upon HSV-1 infection. As shown in Figure 3a , in all cell lines PKR autophosphorylation, in response to HSV infection, was similar to that observed upon treatment of the cells with dsRNA poly [I:C]. Moreover, PKR was able to phosphorylate eIF2a (Figure 3b ). The ratio of the phosphorylated form of eIF2a, with respect to the total eIF2a in cells infected with R3616, confirms that PKR is equally active in all cell lines tested (Figure 3c ).
Effect of translation initiation factor levels in permissiveness of tumour pancreatic cells to g 1 34.5-mutant HSV-1 replication Given the above data, we speculated that elements of cellular signalling downstream of, or parallel to PKR activation and eIF2a phosphorylation could be deregulated in pancreatic tumour cell lines. In fact, as eIF2B is present in rate-limiting amounts in most cells sensitive to eIF2a phosphorylation, an increase in the levels of this protein could enhance translation rates, and possibly neutralize the consequences of eIF2a phosphorylation by increasing the rate of nucleotide exchange on eIF2a. 15 In order to analyse whether the translational control at the eIF2a checkpoint is defective in the four cell lines under study, we focused our attention on the availability of translation initiation factors. In particular, we analysed the levels of eIF2a, eIF2B and eIF4E by immunoblotting ( Figure 4 ). All tumour cell lines displayed significantly Oncolysis of pancreatic tumour cells F Sarinella et al high and comparable levels of eIF2a, eIF2B and eIF4E proteins. Thus, our data suggest that phosphorylated eIF2a is not sufficient to shut-off protein synthesis in tumour cells as the downstream translation factors required for protein synthesis, and in particular eIF2B are available in abundant quantity, thus allowing HSV-1 replication despite PKR antiviral activity. In order to further analyse the role of basal levels of translation initiation factors in the ability of HSV-1 to overcome the cellular antiviral response, we employed primary fibroblastoid MRC5 cells which are characterized by low basal levels of these cellular factors and do not sustain an efficient HSV-1 R3616 replication ( Figure  5a ). MRC5 cells were infected with HSV-1 R3616 in the presence of insulin growth factor (IGF-1), that is known to have an effect on translation initiation factors. 16 A significant increase of viral replication was observed ( Figure 5a ) which correlates with an expected increase (1.8-2.2 fold) in eIF2a, eIF2B and eIF4E translation factors abundance ( Figure 5b ). Thus, enhanced levels of translation initiation factors may play a role in cell permissiveness to viral replication.
The PI 3-kinase pathway is involved in the modulation of limiting translation initiation factor eIF2B levels in tumour pancreatic cells
In order to further confirm our hypothesis and to gain insights on the specific molecular mechanisms involved in the alterations of the translation initiation factors, 
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MiaPaCa-2 21 respectively, were adopted to treat pancreatic cells during infection with R3616 HSV-1. Specific inhibition of PI 3-kinase, mTOR and MAPK pathways was observed under our experimental conditions (data not shown). Figure 6 shows that only treatment with LY294002 is able to determine a significant reduction in R3616 yield in all pancreatic tumour cells (two logs). By contrast, treatment with rapamycin and PD098059 did not appreciably alter viral replication. The same inhibitors did not affect wild-type HSV-1 titers (data not shown). Taken together these results suggest that the PI 3-kinase pathway may contribute to the permissiveness of pancreatic tumour cells to R3616 HSV-1 replication. To test this hypothesis, we investigated the effect of LY294002 on the amount of the limiting translation initiation factor eIF2B. As shown in Figure 7 , treatment of pancreatic tumour cell lines with LY294002 led to a significant decrease of eIF2B (Figure 7a ). In addition, accumulation of eIF2B phosphorylated form was observed ( Figure 7b) . The presence of a basal level of Akt phosphorylation in the pancreatic tumour cells under study (Figure 7c ) supports our conclusions that misregulation of the P I3-kinase pathway may contribute to the ability of the R3616 HSV-1 to replicate in all cell lines tested regardless of their Ras activation state and PKR activity.
Discussion
Oncolytic viruses provide an attractive tool for cancer treatment because of their ability to replicate selectively within the tumour. It has been recently proposed that activated Ras may render tumour cells highly susceptible to viral replication, owing to inhibition of PKR activity.
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HSV-1-based vectors have already been widely proposed for treatment of malignant tumours. 22, 23 Among them, the g 1 34.5-deleted HSV-1 strain (R3616), lacking the ICP34.5 function, cannot revert the effects of PKR activation on protein synthesis and therefore its lytic replication might be expected to be limited to tumour cells that display a Ras-activated pathway.
In this study, we analysed the correlation between R3616 HSV-1 replication and Ras activation state, in a panel of pancreatic cancer cell lines that exhibit either wild-type (physiologically active) or mutated (constitutively active) Ras. We demonstrated that permissiveness of pancreatic tumour cells to R3616 HSV-1 replication does not depend on activated Ras signalling pathway. Indeed, our data show that all cell lines tested sustained R3616 HSV-1 replication, independently from Ras genotype. These results seem at variance with previous literature data, that suggested a direct interaction between a hyper-functioning H-Ras and g 1 34.5-deleted HSV-1 replication in fibroblastoid cell lines. 11 However, significant differences in the experimental approach may contribute to justify this discrepancy. In particular, the pancreatic tumour cell lines we selected naturally present either wild-type or mutant K-ras, instead of being artificially transformed to overexpress H-Ras. It is worth noting that the majority of ras mutations found in human tumours occurs in k-ras, with mutations in h-ras being quite rare. 24 The preferential association of mutant K-Ras protein with human tumours suggests that the function of K-Ras and H-Ras proteins may be significantly different. Thus, the effect of mutations in the respective coding sequences could have a different impact on the cellular physiology and, as a consequence, on viral replication. 24 Moreover, our data clearly show that PKR is fully functional and able to phosphorylate eIF2a in the pancreatic tumour cell lines we studied. Then, we can conclude that the Figure 4 Translation initiation factors expression. Lysates prepared from uninfected cells were examined for levels of eIF2a, eIF2B and eIF4E by immunoblotting using specific antibodies. Representative results from three independent experiments are shown.
Immunoblotting for b-actin is used as a loading control.
Oncolysis of pancreatic tumour cells F Sarinella et al observed permissiveness of pancreatic tumour cell lines to R3616 HSV-1, regardless the Ras status, is not explained by a defective PKR activity. A growing body of evidence has suggested a link between the regulation of protein synthesis, growth control and neoplastic transformation. 25 Events required for the protein synthesis initiation are generally regarded as the rate-limiting steps, with particular attention being paid to the availability and function of the smallest a subunit of eIF2, 26 the guanine nucleotide exchange factor eIF2B 27 and the cap-binding factor eIF4E. 28 eIF2B is a heteropentameric protein, which catalyses a key step in translation initiation, that is the exchange of guanine nucleotides on initiation factor eIF2. 27 In addition, phosphorylation of the a subunit of eIF2 plays a crucial role in protein synthesis control. 29 When eIF2a is phosphorylated, eIF2-GDP binds irreversibly to eIF2B and blocks GDP/GTP recycling and translation initiation is inhibited. As eIF2a is usually more abundant than eIF2B in cells, only partial phosphorylation of eIF2a is sufficient to inhibit most of the eIF2B activity. 29 The pancreatic tumour cells we tested displayed high amounts of eIF2a, eIF2B and eIF4E. We demonstrated that a correlation exists between levels of the above cellular factors and permissiveness to R3616 HSV-1 replication, regardless PKR-mediated cellular antiviral response. Indeed, increased amount of eIF2B renders protein synthesis less sensitive to the inhibitory effects of phosphorylation.
With an excess of translation initiation factors present in pancreatic tumour cells, HSV-1 could be capable to replicate even without ICP34.5, as there is no need to restore a pool of non-phosphorylated eIF2a. Moreover, by using specific inhibitors of signaltransduction pathways, we showed that PI 3-kinase may play a role in R3616 HSV-1 replication in pancreatic tumour cells, regardless of Ras and PKR activity. Indeed, our data indicate that PI 3-kinase may be responsible for the eIF2B activation; neither rapamycin, which blocks activation of mTOR, nor PD098059, which blocks activation of MAP kinase, affects the phosphorylation state of eIF2B. By contrast, LY294002 treatment, which inhibits PI 3-kinase pathway, leads to a significant decrease in eIF2B Figure 7 Effects of treatment with specific inhibitors on translation initiation factors and Akt phosphorylation. Tumour cells were grown to confluence, serum-starved for 12 h and treated with inhibitors for additional 24 h. Cells in the presence of LY294002 show a significant decrease of eIF2B (a) and the appearence of phosphorylated eIF2B (b). Akt shows a basal level of phosphorylation in all cell lines, which is sensitive to LY294002 treatment. The cell extracts were probed using a phosphorylation state-independent antibody that detects the epsilon subunit of eIF2B (a), a phosphospecific eIF2B (b), or a phosphospcific Akt antibody (c). Immunoblotting for b-actin is used as a loading control.
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F Sarinella et al amount and to the accumulation of eIF2B phosphorylated form. It has been reported that activated PI 3-kinase can phosphorylate and inactivate glycogen synthase kinase-3 (GSK-3); 30 GSK-3 phosphorylates the epsilonsubunit of eIF2B, leading to inhibition of its guanidine nucleotide exchange activity. 31 Thus, inactivation of GSK-3 and consequent activation of eIF2B, results in enhanced nucleotide exchange on eIF2, increased availability of its active GTP-bound form (eIF2-GTP) 31 and in general upregulation of protein synthesis. 30, 31 Based on these findings, we suggest that a PI 3-kinase pathway miss-regulation may contribute to the accumulation of the limiting translation initiation factor eIF2B. Therefore, in cells where PI 3-kinase is miss-regulated, protein translation may become independent from PKR activity, allowing efficient replication of g 1 34.5-deleted HSV-1 (Figure 8) .
Our results, while showing that HSV-1 can indeed efficiently lyse pancreatic tumour cell lines, they pose safety and specificity issues. The design of a safe and specific oncolytic virus should involve a precise dissection of the genetic background of the target tumour cells, in order to mutate the virus accordingly. To this regard, our study prompts to investigate genes involved in protein synthesis control in naturally arising tumours. On the other hand, the oncolytic virus should be deleted in a number of functions so that its replication becomes dependent on different cellular pathways. Owing to HSV-1 genomic complexity and its high efficiency of replication, this could be achieved by combining deletions in different functions involved, for instance, in pyrimidyne pathways and DNA synthesis (i.e. UG (Uracil DNA Glycosylase) 32 and RR (Ribonucleotide Reductase) 33 ), as already proposed by other groups. 32, 33 However, it should be kept in mind that for tumours localized in specific districts, such as in the central nervous system, ICP34.5-deleted HSV presents a high level of selectivity/safety, provided by multiple mechanisms, resulting from the multifunctional nature of ICP34.5 itself. In particular, in nondividing cells, ICP34.5 is required to switch the cellular protein PCNA from repair to replication mode, a prerequisite for the initiation of HSV replication. 34 This renders ICP34. 5-deleted HSV a safe and selective oncolytic agent for the treatment of brain tumours. In conclusion, as the genetic complexity of several tumours can be particularly high and pathways not traditionally taken into account as target for oncogenic mutations may instead being involved, a large-scale screening of tumour and non-tumour cells of different origin by microarray techniques may be extremely useful as a basis for tailoring safe and potent oncolytic viruses. 
Materials and methods
Cell lines
Viral strains
Wild-type HSV-1 strain F, HSV-1 (F), and mutated HSV-1 R3616, which has a 1-kb deletion within both regions encoding g34.5, 35 were a kind gift of Professor Bernard Roizman (University of Chicago, IL, USA). Viral stocks were obtained and titered as previously described. 36 
Reagents
Antibodies against PKR, eIF2a and secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against phospho-PKR, eIF2a, eIF4E, eIF2B (epsilon subunit), phospho-eIF2B, and phospho-AKT were purchased from Cell Signaling Technologies, Inc. (Beverly, MA, USA); antibody against all HSV-1 antigens was from Dako Cytomation (Glostrup, Denmark); antibody against tubulin was from Sigma Aldrich (Milan, Italy). Rapamycin was obtained from Calbiochem-Novabiochem (San Diego, CA, USA). PD098059 was obtained from New England Biolabs, Inc. (Beverly, MA, USA). LY294002 was purchased from Cell Signaling Technologies, Inc. Enhanced chemiluminescence reagents were from Amersham Biosciences Europe GMBH (Freiburg, Germany). All the reagents were of the purest grade available.
Activated Ras affinity precipitation assay
Raf Ras-binding domain (RBD) fragment (Raf-1 aminoacid residues 1-149) fused to GST was purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). The fusion protein was immobilized on glutathione-agarose. The activated Ras affinity precipitation assay was performed as described according to the manufacturer's protocol. Briefly, 500 mg of cell extracts were incubated with 5 mg of GST-RBD complexes for 30 min at 41C. After extensive washing of the agarose beads five times with immunoprecipitation washing buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl 2 , 1 mM EDTA, and 2% glycerol), the active Ras (Ras-GTP) bound to GST-RBD complexes was released by addition of 2 Â SDS/polyacrylamide gel electrophoresis loading buffer. The amount of active Ras was determined by immunoblotting with an anti-Ras monoclonal antibody (clone RAS10, Upstate Biotechnology, Inc.).
Viral proliferation
For viral replication assays, pancreatic tumour cells were grown to 80% confluence and subsequently infected at the MOI of 1 and 10 PFU per cell with either HSV-1 F or R3616 strains. At the latter MOI, 100% of the cells evaluated by immunofluorescence assay with a polyclonal antibody specific for HSV-1 (see above), resulted infected. The supernatants of HSV-infected cells were harvested at various time points p.i. Viral titers were determined from the supernatants of samples by plaque assay on Vero cells. 36 All samples were analysed in triplicate.
Immunoblot analysis
Control and infected cells were lysed at indicated time points with lysis buffer (10 mM Tris-HCl (pH 7.4), 400 mM NaCl, 5 mM NaF, 10% glycerol, 5 mM EDTA, 0.5% Nonidet, 1 mM sodium orthovanadate (Na 3 VO 4 ), 4 mM DTT, 100 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, and 10 mg/ml aprotinin). After centrifugation to remove debris, the protein extracts were recovered and stored at À801C until use. Protein concentrations were determined using the Pierce BCA Protein Assay Kit (Pierce Biotechnologies, Inc. Rockford, IL, USA). Whole-cell extracts (50 mg) were separated on 12.5% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked with PBS containing 0.05% Tween 20 and 5% dry milk, probed with primary specific antibody and then treated with appropriate horseradish peroxidaseconjugated secondary antibodies. Immunoreactive proteins were visualized using the Enhanced Chemiluminescence Western-blotting detection system (Amersham Biosciences). Densitometric analysis was performed by scanning immunoblots and quantitating protein bands using Quantity One software (Bio-Rad Laboratories).
Treatment with IGF-1
MRC-5 were maintained in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum. Before treatment, cells were grown to 80% confluence before being serum-starved for 18 h. Cells were then treated with IGF-1 (100 ng/ml) for 1 h. Cells were infected with HSV-1 (both F and R3616) at the MOI of 10 PFU per cell in serum-free medium in the presence or in the absence of IGF-1. At 24 h p.i., cells were lysed and supernatants were analysed for virus production by plaque assay.
Treatment with inhibitors
PT45, PSK-1, MiaPaCa-2 and PaCa-3 cells were washed twice in serum-free DMEM and incubated in fresh DMEM for additional 24 h. Cells were then treated with LY294002, PD098059 or rapamycin for 1 h and then either infected with HSV-1 or mock infected. After 24 h, the supernatants were collected to determine virus titer and the cells were lysed in 50 mM Tris-HCl, 5 mM EDTA, 100 mM NaCl, 40 mM b-glycerophosphate, 50 mM NaF, 1 mM Na 3 VO 4 , 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml leupeptin (pH 7.6).
Note added in proof
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